September: Nevro earned FDA approval and began a limited market release of its HFX iQ spinal cord stimulator with HFX AdaptivAI. October: Allied Market Research forecasts the spinal cord stimulator ...

Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...

Globus Medial completed its acquisition of Nevero, a spinal cord stimulator company, according to an April 3 news release. The acquisition expands Globus Medical’s reach in the musculoskeletal market ...

Multiple sclerosis causes lesions to the spinal cord and other parts of the central nervous system. An MRI can detect spinal cord lesions and help diagnose and monitor the condition. Multiple ...

Nevro develops implantable spinal cord stimulation (SCS) technology. It also offers sacroiliac (SI) joint fusion platforms. The company’s HFX iQ SCS system utilizes AI, high-frequency (10 ...

Conclusions This report presents a case where spinal cord stimulation for neuropathic pain resulted in an improvement in the patient's Parkinsonian symptoms. We suggest that future studies should ...

It works across orthopaedic trauma, spine, biomaterials, joint reconstruction and enabling technologies, offering education and clinical backing. Nevro’s HFX spinal cord stimulation platform (SCS) ...

Nevro’s comprehensive HFX spinal cord stimulation (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

At close: April 2 at 4:00:02 PM EDT ...